Lens incorporating myopia control optics and muscarinic agents

• US 9,827,250 B2
• Filed: 07/31/2012
• Issued: 11/28/2017
• Est. Priority Date: 07/31/2012
• Status: Active Grant

• Current Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Original Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Inventors: Chehab, Khaled, Shedden, Jr., Arthur H., Cheng, Xu
• Primary Examiner(s): Mack, Ricky
• Assistant Examiner(s): Manikeu, Daniele
• Application Number:
  US13/563,322
• Publication Number:
  US 20140036225A1
• Time in Patent Office: 1,946 Days
• Field of Search: 623 511- 662, 424427-429, 35115901-15981, 604289-316
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: G02C 2202/24 Myopia progression prevention
• CPC Class Codes: G02C 7/04 Contact lenses for the eyes disinfection or sterilisation of contact lenses A61L12/00
• CPC Class Codes: G02C 7/041 bifocal; multifocal

Abstract

Ophthalmic devices, such as contact lenses, may incorporate myopia control optics in combination with therapeutic agents also known to control myopia to create a drug delivery mechanism to inhibit or arrest the progression of myopia in individuals. Any number of contact lenses incorporating myopia control optics may be combined with a therapeutic agent such as atropine, atropine sulphate monohydrate, and/or pirenzepine.

Claims

1. An ophthalmic lens system for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens system comprising:

a contact lens formed from at least one of a hydrogel or silicon hydrogel material and incorporating myopia control optics and one or more of single vision optics, astigmatism optics, bifocal optics, and multifocal optics, the contact lens including an optic zone having a central zone surrounded by at least one region that is configured to provide positive longitudinal spherical aberrations that continuously and progressively increase away from the center of the lens, the central zone including between 0.25 and 1.00 diopters of additional distance power correction;

a blister package that contains the contact lens; and

a solution within the blister package;

the solution comprising atropine sulphate monohydrate and buffered saline infused via swelling into the contact lens in an amount sufficient to deliver between 0.0005 and 0.5 mg of atropine sulphate monohydrate to a patient'"'"'s eye over the course of a single day with a cumulative delivery having a profile of an initial burst of up to about 2 mg within the first hour, up to 3 mg within the next hour and up to about 4 mg over the next 9 hours;

the solution chemically structured to create synergistic effect to increase myopia progression control.

2. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, further comprises a photochromic agent incorporated into the contact lens.

3. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, further comprises a neutral filter dye incorporated into the contact lens.

4. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the contact lens comprises a daily wear lens.

5. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to claim 1, wherein the contact lens comprises a reusable lens.